Emergent BioSolutions EBS
NYSE EBS
$6.32 +0.03 (+0.48%)
As of: Oct 21, 2026 · 9:54 AM EDT

Emergent BioSolutions (EBS) Current Deferred Revenue (2010 - 2026)

Updated

Emergent BioSolutions' Current Deferred Revenue was $15 million in Q2 2026, up 23.0% from the prior quarter.

Analysis

Emergent BioSolutions (EBS) Current Deferred Revenue (2010 - 2026) Analysis & Trends

At the end of FY2025, Current Deferred Revenue at Emergent BioSolutions came in at $5 million.

  • The Q2 2026 figure marks the highest quarterly Current Deferred Revenue since Q2 2020.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,139.37 Bn 1,107.95 Bn 19.71 Bn
2 Johnson & Johnson 618.39 Bn 536.92 Bn 17.26 Bn
3 AbbVie 508.07 Bn 481.19 Bn 12.70 Bn
4 Merck 367.07 Bn 321.44 Bn 12.21 Bn
5 Novartis Ag 298.65 Bn 262.64 Bn 11.24 Bn
6 Astrazeneca 263.08 Bn 236.77 Bn 12.86 Bn
7 Amgen 236.65 Bn 192.05 Bn 7.24 Bn
8 Gilead Sciences 192.73 Bn 166.92 Bn 6.22 Bn
9 Pfizer 171.28 Bn 117.93 Bn 10.94 Bn
10 Emergent BioSolutions 327.66 Mn -423.24 Mn 137.20 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 15.00 Mn
Mar 31, 2026 12.20 Mn
Dec 31, 2025 5.00 Mn
Jun 30, 2020 32.70 Mn
Dec 31, 2019 3.30 Mn
Dec 31, 2018 10.60 Mn
Sep 30, 2018 10.79 Mn
Jun 30, 2018 9.75 Mn
Mar 31, 2018 6.96 Mn
Dec 31, 2017 13.20 Mn
Sep 30, 2017 4.51 Mn
Jun 30, 2017 15.41 Mn
Mar 31, 2017 10.65 Mn
Dec 31, 2016 7.04 Mn
Sep 30, 2016 4.82 Mn
Jun 30, 2016 7.13 Mn
Mar 31, 2016 9.59 Mn
Dec 31, 2015 3.98 Mn
Sep 30, 2015 8.73 Mn
Jun 30, 2015 7.34 Mn
API Access

Emergent BioSolutions Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=EBS&period=max&api_key=YOUR_API_KEY